SCHEMBL6467489

SCHEMBL6467489

NC(CC(=O)O)SCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 3/20 0.46
CPA1 P15085 2/20 0.46
CPB1 P15086 1/20 0.46
CPA3 P15088 1/20 0.46
CPB2 Q96IY4 1/20 0.46
ALDH1A1 P00352 1/20 0.44
POLB P06746 1/20 0.44
CYP2C9 P11712 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALPI P09923 1/20 0.44
PKM P14618 1/20 0.44
PTGS1 P23219 1/20 0.44
XIAP P98170 1/20 0.44
SLC7A5 Q01650 1/20 0.44
IDO1 P14902 3/20 0.43
EPHX1 P07099 2/20 0.43
SLC15A1 P46059 1/20 0.42
AKR1B1 P15121 1/20 0.42
GABBR2 O75899 1/20 0.42
GABBR1 Q9UBS5 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL6467921 0.98 IDO1 (0.45) CYP2C19CPA1CPB1CPA3CPB2
SCHEMBL6741702 0.84 CYP2C19 (0.48) CYP2C19ALDH1A1POLBCYP2C9SMN1; SMN2
SCHEMBL7540831 0.81 CYP2C19 (0.63) CYP2C19CPA1CPB1CPA3CPB2
Ethylamine SCHEMBL11235220 0.78 CYP2C19 (0.63) CYP2C19CPA1CPB1CPA3CPB2
SCHEMBL27862584 0.78 PPARG (0.48) CYP2C19CPA1CPB1CPA3CPB2
SCHEMBL4016741 0.76 PDPK1 (0.47) CYP2C19CPA1CPB1CPA3CPB2
SCHEMBL7544290 0.76 CTSS (0.46)
SCHEMBL6466445 0.76 DPP4 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL29249083 0.75 CYP2C19 (0.47) CYP2C19CPA1CPB1CPA3CPB2
SCHEMBL6576148 0.75 CYP2C19 (0.43) CYP2C19CPA1CPB1CPA3CPB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1516877-A1 Amine derivatives as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2005-03-23 EP disclosed
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-12-18 US disclosed
US-6576630-B1 Alkanoyl substituted benzooxazoles or naphthooxazoles AXYS PHARMACEUTICALS, INC. 2003-06-10 US disclosed
EP-1161422-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2001-12-12 EP disclosed
WO-2000055144-A1 AMINE DERIVATIVES AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2000-09-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232864-A1 Novel Compounds and compositions as protease inhibitors SERPINB1, CTRL, CTSZ CYP2C19 1822/4885CPA1 67/4885CPB1 47/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.